Bristol Myers Squibb beats profit estimates

What happened: Bristol Myers Squibb (BMY) reported strong Q2 results, beating profit estimates and raising its 2026 forecast. Key drivers were robust sales of blood thinner Eliquis (up 14%) and newer drugs like Camzyos. Vertex Pharmaceuticals (VRTX) also impressed with an 8-fold surge in sales of its new cystic fibrosis drug. BMY's growth portfolio, including these drugs, contributed significantly to its performance.

Market impact: This narrative positively impacts the pharmaceutical sector, with BMY shares up 4% post-Q1 results and 5% post-Q2 results. Investors favor companies with strong pipelines and robust sales growth. VRTX's success also bodes well for other companies developing treatments for rare diseases.

What to watch next: BMY's Q3 earnings call on August 2, 2023, will provide further insights into its growth trajectory. Additionally, investors await updates on VRTX's cystic fibrosis pipeline, with the company's R&D pipeline review expected in Q4 2023. Lastly, regulatory decisions on BMY's and VRTX's pipeline drugs will influence future growth prospects.